TX-ONESOURCE/CLOUDPAY
OneSource Virtual (OSV), a leading Business Process as a Service (BPaaS) provider and CloudPay, one of the world's foremost providers of managed global payroll and payment services, today announced an alliance to deliver comprehensive HR and international payroll to global organizations.
This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20160920005400/en/
OneSource Virtual and CloudPay will offer a Global Workforce Administration service, which will enable organizations to reduce the time, effort and costs of global HR and payroll administration through technology, integration, services and superior customer support.
"The complexities of payroll and the demand for accuracy have dramatically increased across the globe. As a result, there's a necessity for a streamlined, global HR and payroll solution," says Trey Campbell, president and COO of OneSource Virtual. "Collaborating with CloudPay will allow us to expand our HR and payroll outsourcing services globally and deliver more value to existing customers with multinational operations, as well as develop new partnerships with international organizations looking for a truly global HR and payroll solution."
CloudPay brings a singular focus on technology-enabled solutions and breadth of international payroll capabilities. These qualities are key to the successful service delivery model, and are consistent with OneSource Virtual’s position as the leader in BPaaS solutions.
“We’re excited to bring our SaaS global payroll solution to even more enterprises through our alliance with OSV, a leader in workforce administration,” says Brian Radin, chief revenue officer of CloudPay. “CloudPay’s alliance with OSV will provide multi-national organizations with a fully-integrated HR and payroll experience through a single platform and from one service provider.”
About OneSource Virtual
Founded in 2008, OneSource Virtual is a pioneer of Business Process as a Service (BPaaS) and supports the automated delivery of solutions exclusively for Workday. OneSource Virtual’s services empower organizations of all sizes by encouraging HR and Finance to become a strategic partner within the organization, aligning to business growth and scaling by demand through Workday deployment, consulting, training, and in-application payroll administration, benefit administration and application management services. OneSource Virtual is headquartered in Irving, Texas, with processing centers in Mesa, Ariz., and Derry, Northern Ireland. For more information, please visit www.onesourcevirtual.com .
About CloudPay
CloudPay is the next generation payroll solution for multinational businesses with complex global payroll requirements. CloudPay is the world’s only cloud-based platform for integrated global payroll, analytics and payments processing and delivery. Their solution ensures that employees get accurate and timely payments while centralizing all payroll data to allow organizations to improve the performance of their global operations. With CloudPay's unique analytical toolset, companies can turn their payroll data into meaningful business insights, and use CloudPay’s compliance tracking functionality to assure continuous compliance with all local and statutory regulations and tax requirements. For more information please visit www.cloudpay.net .
View source version on businesswire.com: http://www.businesswire.com/news/home/20160920005400/en/
Contact:
OneSource Virtual
Tristan Desinor, 469-351-2422
tdesinor@onesourcevirtual.com
or
CloudPay
David
Barak, 347-338-0066
press@cloudpay.net
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vertex Receives CHMP Positive Opinion for ALYFTREK®, a New Once-Daily CFTR Modulator for the Treatment of Cystic Fibrosis28.4.2025 08:03:00 CEST | Press release
- ALYFTREK®(deutivacaftor/tezacaftor/vanzacaftor) recommended for people with CF ages 6 years and older with at least one non-class I mutation in the CFTR gene -- In head-to-head clinical trials, deutivacaftor/tezacaftor/vanzacaftor was non-inferior on ppFEV1 and superior compared to KAFTRIO® (ivacaftor/tezacaftor/elexacaftor) at reducing sweat chloride - Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for ALYFTREK®(deutivacaftor/tezacaftor/vanzacaftor)for the treatment of people with cystic fibrosis (CF) ages 6 years and older who have at least one non-class I mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. “Our goal has always been to serially innovate to help people with cystic fibrosis live healthier and longer lives. If approved, this new medicine would be indicated for people with CF ages 6 years and older with at least
Prilenia Enters into a Collaboration and License Agreement with Ferrer for the Commercialization and Co-Development of Pridopidine in Europe and Other Select Markets28.4.2025 07:02:00 CEST | Press release
-- Total deal size of approximately €500 million, including approximately €125 million in upfront and near-term milestones ---- Ferrer to commercialize pridopidine in Europe and other select markets; Prilenia retains full commercialization and development rights to pridopidine in North America, Japan and Asia Pacific ---- Co-development agreement in the territory supports further expansion of pridopidine in Huntington’s disease, amyotrophic lateral sclerosis and future indications ---- Pridopidine for Huntington’s disease is currently under review by the European Medicines Agency (EMA) with a CHMP opinion expected in the second half of 2025 -- Prilenia Therapeutics B.V., a biopharmaceutical company driven by an unwavering commitment to scientific excellence and accelerating progress for people affected by Huntington’s disease (HD) and amyotrophic lateral sclerosis (ALS), today announced that it has entered into a collaboration and license agreement with Ferrer for the commercialization
Ferrer Enters Into a Collaboration and License Agreement With Prilenia for the Commercialization and Co-Development of Pridopidine28.4.2025 07:00:00 CEST | Press release
Ferrer, an international B Corp pharmaceutical company with an increasing focus on rare neurological diseases, and Prilenia Therapeutics B.V.,a clinical-stage biotech company, have announced the signing of a strategic co-development and license agreement in which Ferrer obtains the rights to develop, manufacture and commercialize Pridopidine in the European Region, the Middle East and North African Region, the Southern African Region, the Central and South American Region, and the Commonwealth of Independent States Region. Pridopidine, a potent and highly selective, orally administered sigma-1 receptor agonist, designed to regulate key neuroprotective mechanisms that are often impaired in neurodegenerative diseases, is a promising candidate for the treatment of Huntington’s Disease (HD), a rare inherited neurodegenerative disease, with a high unmet medical need1. It has been studied in more than 1,700 people and long-term safety data of up to 7 years duration are available from previou
Innorna Announces FDA Rare Pediatric Disease and Orphan Drug Designations Granted to IN013 for Treatment of Wilson Disease27.4.2025 11:36:00 CEST | Press release
Innorna, a clinical-stage biotechnology company revolutionizing mRNA therapeutics with its innovative lipid nanoparticle (LNP) delivery technology, today announced the U.S. Food and Drug Administration (FDA) has granted both Rare Pediatric Disease Designation (RPDD) and Orphan Drug Designation (ODD) to its investigational mRNA therapy, IN013, for treating Wilson Disease (WD). This dual achievement accelerates the clinical development of IN013, advancing Innorna’s mission to deliver transformative therapies for WD patients. About FDA Designations The Rare Pediatric Disease Designation (RPDD) incentivizes therapies for serious or life-threatening diseases affecting fewer than 200,000 U.S. patients, primarily those aged 18 or younger. Sponsors may qualify for a Priority Review Voucher (PRV) upon approval to expedite FDA review of a subsequent drug application. The Orphan Drug Designation (ODD) supports therapies targeting rare diseases (affecting fewer than 200,000 U.S. patients) by provi
Everen Specialty Appoints Carla Greaves Chief Underwriting Officer25.4.2025 19:00:00 CEST | Press release
Everen Specialty, a Bermuda-based (re)insurer for energy markets worldwide, today announced the appointment of Carla Greaves as its new Chief Underwriting Officer (CUO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250425273777/en/ Carla Greaves Ms. Greaves will join the Executive Leadership Team of the Everen Group, based in the Bermuda office, later this year. She succeeds Jane Peterson, Interim CUO, who will continue in a consultancy capacity to facilitate the transition. With more than 30 years of underwriting and leadership experience in the (re)insurance industry, Ms. Greaves brings a wealth of expertise and a proven track record of success in the Casualty market where she is recognized for building high-performing teams, driving profitable growth, and successfully navigating complex market environments. Prior to joining Everen Specialty, Ms. Greaves held increasingly senior leadership positions, most recently servin
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom